160 related articles for article (PubMed ID: 34328007)
1. Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report.
Yhim HY; Jeon SY; Lee CH; Lee NR
Ann Palliat Med; 2022 Jun; 11(6):2162-2169. PubMed ID: 34328007
[TBL] [Abstract][Full Text] [Related]
2. Lynch Syndrome: Its Impact on Urothelial Carcinoma.
Lindner AK; Schachtner G; Tulchiner G; Thurnher M; Untergasser G; Obrist P; Pipp I; Steinkohl F; Horninger W; Culig Z; Pichler R
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430305
[TBL] [Abstract][Full Text] [Related]
3. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral Cancer].
Kobayashi G; Takayanagi A; Shindo T; Hashimoto K; Kobayashi K; Fukuta F; Tanaka T; Masumori N
Hinyokika Kiyo; 2021 Jun; 67(6):229-232. PubMed ID: 34265897
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT in a Case of Lynch Syndrome With Synchronous Inverted Urothelial Papilloma of the Bladder, Urothelial Carcinoma of the Ureter, and Jejunal Adenocarcinoma.
Zhao Q; Dong A; Wang Y
Clin Nucl Med; 2022 Jan; 47(1):e11-e13. PubMed ID: 34172598
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
7. Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
Tua-Caraccia R; Livingston A; Routh JC
Urology; 2023 Nov; 181():133-135. PubMed ID: 37422136
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma.
Ma YT; Yang HL; Yan L; Hua F; Wang DG; Xu GY; Li Y; Xue YJ; Qin YJ; Sha D; Ning H; Zhao MQ; Yao ZG
Pathol Oncol Res; 2022; 28():1610638. PubMed ID: 36338826
[TBL] [Abstract][Full Text] [Related]
9. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
[TBL] [Abstract][Full Text] [Related]
10. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
[TBL] [Abstract][Full Text] [Related]
12. Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer.
Lin J; Sabath BF
Am J Case Rep; 2021 Oct; 22():e933396. PubMed ID: 34606491
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
14. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
15. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
16. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
17. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors.
Lonati C; Necchi A; Gómez Rivas J; Afferi L; Laukhtina E; Martini A; Ventimiglia E; Colombo R; Gandaglia G; Salonia A; Briganti A; Montorsi F; Mattei A; Simeone C; Carlo MI; Shariat SF; Spiess PE; Moschini M;
Eur Urol Oncol; 2022 Feb; 5(1):30-41. PubMed ID: 34896051
[TBL] [Abstract][Full Text] [Related]
18. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
19. Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.
Hemminger JA; Pearlman R; Haraldsdottir S; Knight D; Jonasson JG; Pritchard CC; Hampel H; Frankel WL
Hum Pathol; 2018 Aug; 78():125-130. PubMed ID: 29723603
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
Küronya Z; Danyi T; Balatoni T; Liszkay G; Tóth E; Biró K; Géczi L
J Med Case Rep; 2022 Oct; 16(1):396. PubMed ID: 36316780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
